BioPharma Dive

Obsidian, Galera to advance cell therapy following reverse merger

The combined company will trade on the Nasdaq under the ticker OBX. It has also secured commitments for a private placement expected to deliver $350 million in gross proceeds.
Seeking Alpha

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

PHILADELPHIA and MALVERN, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Carisma Therapeutics Inc. (CARM) (Carisma) and OrthoCellix, Inc. (OrthoCellix), a wholly-owned subsidiary of Ocugen, Inc. (Ocugen), a ...
Nasdaq

Carisma Therapeutics and OrthoCellix Announce Proposed Reverse Merger to Form Nasdaq-Listed Regenerative Cell Therapy Company

Carisma Therapeutics Inc. and OrthoCellix, a subsidiary of Ocugen, have announced a definitive merger agreement to create a Nasdaq-listed regenerative cell therapy company. The merger, which will be ...
PharmExec

Obsidian Therapeutics and Galera Therapeutics Enter $350 Million Merger Agreement

A reverse-merger structure uses Galera’s public listing and cash to bring Obsidian public, while Madan Jagasia is slated to lead the combined company. Financing comprises a $350 million concurrent ...
The Business Journals

After laying off most of its staff, struggling Carisma Therapeutics finds a merger partner

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min After a tumultuous year of ...
Nasdaq

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

PHILADELPHIA and MALVERN, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Carisma Therapeutics Inc. (Nasdaq: CARM) (Carisma) and OrthoCellix, Inc. (OrthoCellix), a wholly ...